Linezolid Alone and in Combination with Rifampicin Prevents Experimental Vascular Graft Infection Due to Methicillin-Resistant Staphylococcus aureus and Staphylococcus epidermidis

Journal of Surgical Research

Volumn 139, Issue 2, 2007, Pages 170-175

  Sacar, Mustafa ^a   Sacar, Suzan ^a   Kaleli, Ilknur ^a   Onem, Gokhan ^a   Turgut, Huseyin ^a   Goksin, Ibrahim ^a   Ozcan, Vefa ^a   Kaan Inan, Bilal ^b   Duver, Harun ^c   Baltalarli, Ahmet ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

^b GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^c 82nd Year State Hospital   (Turkey)

Author keywords

linezolid; prosthetic graft infection; rifampin; teicoplanin

Indexed keywords

LINEZOLID; RIFAMPICIN; TEICOPLANIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD VESSEL GRAFT; COLONY FORMING UNIT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DACRON IMPLANT; DRUG POTENTIATION; GRAFT INFECTION; IN VIVO STUDY; INFECTION PREVENTION; INOCULATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; STAPHYLOCOCCUS EPIDERMIDIS; SUBCUTANEOUS TISSUE;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BLOOD VESSEL PROSTHESIS; DRUG SYNERGISM; MALE; METHICILLIN RESISTANCE; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; RATS; RATS, WISTAR; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TEICOPLANIN;

EID: 34047251857     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.10.003     Document Type: Article

References (44)

1. Bergamini T.M., Corpus R.A., Brittian K.R., et al. The natural history of bacterial biofilm graft infection. J Surg Res 56 (1994) 393
2. Bergamini T.M., Peyton J.C., and Cheadle W.G. Prophylactic antibiotics prevent bacterial biofilm graft infection. J Surg Res 52 (1992) 101
3. Bandyk D.F. Infection in prosthetic vascular grafts. In: Rutherford R.B. (Ed). Vascular Surgery. 5th edition (2000), Saunders, Philadelphia, PA 733
4. Raza Z., Newton D.J., Harrison D.K., et al. Disruption of skin perfusion following longitudinal groin incision for infrainguinal bypass surgery. Eur J Vasc Endovasc Surg 17 (1999) 5
5. Citak M.S., Cue J.I., Peyton J.C., et al. The critical relationship of antibiotic dose and bacterial contamination in experimental infection. J Surg Res 52 (1992) 127
6. Chervu A., Moore W.S., Gelabert H.A., et al. Prevention of graft infection by use of prostheses bonded with a rifampin/collagen release system. J Vasc Surg 14 (1991) 521
7. Osada T., Yamamura K., Fujimoto K., et al. Prophylaxis of local vascular graft infection with levofloxacin incorporated into albumin-sealed Dacron graft (LVFX-ALB Graft). Microbiol Immunol 42 (1999) 317
8. Shue W.B., Worosilo S.C., Donetz A.P., et al. Prevention of vascular prosthetic infection with an antibiotic-bonded Dacron graft. J Vasc Surg 8 (1988) 600
9. Sacar M., Goksin I., Baltalarli A., et al. The prophylactic efficacy of rifampicin-soaked graft in combination with systemic vancomycin in the prevention of prosthetic vascular graft infection: an experimental study. J Surg Res 129 (2005) 329
10. Turgut H., Sacar S., Kaleli I., et al. Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection. BMC Infect Dis 5 (2005) 91
11. Kaiser A.B., Clayson K.R., Mulherin Jr. J.L., et al. Antibiotic prophylaxis in vascular surgery. Ann Surg 188 (1978) 283
12. Hasselgren P.O., Ivarson L., Risberg B., et al. Effects of prophylactic antibiotics in vascular surgery. A prospective randomized double blind study. Ann Surg 200 (1984) 86
13. Campoli-Richards D.M., Brodgen R.N., Faulds D., et al. Teicoplanin: A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs 40 (1990) 449
14. Calain P., and Waldwogel F. Clinical efficacy of teicoplanin. Eur J Clin Microbiol Infect Dis 9 (1990) 127.
15. Wilson A.P.R., and Gruneberg R.N. Use of teicoplanin in community medicine. Eur J Clin Microbiol Infect Dis 13 (1994) 701
16. Center for Disease Control and prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb Mortal Wkly Rep 46 (1997) 813
17. Stevens D.L., Dotter B., and Madaras-Kelly K. A review of linezolid: The first oxazolidinone antibiotic. Expert Rev Anti-Infect Ther 2 (2004) 51
18. Swaney S.M., Aoki H., Clelia Ganoza M., et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 42 (1998) 3251
19. Sano K., and Tunakawa N. Chemistry of rifampicin. Med Treatment 23 (1970) 928
20. Ashton T.R., Cunningham J.D., Patan D., et al. Antibiotic loading of vascular grafts. Proceedings of the Sixteenth Annual Meeting of the Society of Biomaterials, Charleston 13 (1990) 235
21. Brissonniere O.G., Leport C., Bacourt F., et al. Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg 5 (1991) 408
22. Institute of Laboratory Animal Resources, National Research Council. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington, DC
23. Kloos W.E., and Barnerman T.L. Staphylococcus and Micrococcus. In: Murray P.R., Baron E.J., Pfaller M.A., et al. (Eds). Manual of Clinical Microbiology. 7th edition (1999), ASM Press, Washington, DC 264
24. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disc Susceptibility Tests-Approved Standards M2-A6 (1997), NCCLS, Wayne, PA
25. Bunt T.J. Sources of Staphylococcus epidermidis at the inguinal incision during peripheral revascularization. Am Surg 52 (1986) 472
26. Liekweg W.G., and Greenfield L.J. Vascular prosthetic infections: Collected experience and results of treatment. Surgery 81 (1977) 335
27. Lorentzen J.E., Neilson O.M., Arendrup H., et al. Vascular graft infection: An analysis of sixty-two infections in 2411 consecutively implanted synthetic vascular grafts. Surgery 98 (1985) 81
28. Earnshaw J.J. Methicillin-resistant Staphylococcus aureus: Vascular surgeons should fight back. Eur J Vasc Endovasc Surg 23 (2002) 127
29. Naylor A.R., Hayes P.D., and Darke S. A prospective audit of complex wound and graft infections in Great Britain and Ireland: The emergence of MRSA. Eur J Vasc Endovasc Surg 21 (2001) 289
30. Schmitt D.D., Bandyk D.F., Pequet A.J., et al. Bacterial adherence to vascular protheses. J Vasc Surg 3 (1986) 732
31. Farr B., and Mandell G.L. Rifampicin. Med Clin North Am 66 (1982) 157
32. Lenhgharardit F.J., Torsello G., Claeys L.G.Y., et al. Systemic and local antibiotic prophylaxis in the prevention of prosthetic vascular graft infection: An experimental study. Eur J Vasc Surg 23 (2002) 127
33. Gahtan V., Esses G.E., Bandyk D.F., et al. Antistaphylococcal activity of rifampin-bonded gelatin-impregnated Dacron grafts. J Surg Res 58 (1995) 105
34. Marples R.R., and Cooke E.M. Current problems with methicillin-resistant Staphylococcus aures. J Hosp Infect 11 (1988) 381
35. Hayes P.D., Nasim A., London N.J.M., et al. In situ replacement of infected aortic grafts with rifampicin-bonded prostheses: The Leicester experience (1992 to 1998). J Vasc Surg 30 (1999) 92
36. Cepeda J.A., Whitehouse T., Cooper B., et al. Linezolid versus teicoplanin in the treatment of gram-positive infections in the critically ill: A randomized, double-blind, multicenter study. J Antimicrob Chemother 53 (2004) 345
37. Gander S., Hayward K., and Finch R. An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model. J Antimicrob Chemother 49 (2002) 301
38. Dailey C.F., Pagano P.J., Buchanan L.W., et al. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 47 (2003) 2655
39. Ford J.W., Hamel J.C., Wilson D.M., et al. In vivo activities of U-100592 and U-10076 novel oxazolidinone antimicrobial agents against experimental bacterial infections. Antimicrob Agents Chemother 40 (1996) 1508
40. Wood M.J. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 37 (1996) 209
41. Hiramatsu K., Hanaki H., Into T., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135
42. Henwood J.C., Livermore D.M., Johnson A.P., et al. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 46 (2000) 931
43. Livermore D.M. Linezolid in vitro: Mechanism and antibacterial spectrum. J Antimicrob Chemother 51 (2003) 9
44. Abb J. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: Comparative evaluation by the E test and a broth microdilution method. Diagn Microbiol Infect Dis 43 (2002) 319